We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A new Medicaid rule being proposed by the Centers for Medicare & Medicaid Services (CMS) could discourage generic drug use and should be amended to reflect actual acquisition costs for retailers that fill prescriptions with generic drugs, a pharmacist group said.
A new Medicaid rule being proposed by the Centers for Medicare & Medicaid Services (CMS) could discourage generic drug use and should be amended to reflect actual acquisition costs for retailers that fill prescriptions with generic drugs, a pharmacist group said.
Healthcare spending will continue to grow more quickly than the economy over the next decade as more Americans join government-provided healthcare programs, according to a report from economists at the Centers for Medicare & Medicaid Services (CMS).
Motivated by lower co-payments for inexpensive alternatives to brand drugs, more Medicare Part D participants selected generic drugs to fill prescriptions covered by the drug benefit program last year than in 2005, according to new data from the Centers for Medicare & Medicaid Services (CMS).
The kinds of information the Centers for Medicare & Medicaid Services (CMS) relies on when making coverage decisions may not be what firms expect, as one company recently found out.
Motivated by lower co-payments for inexpensive alternatives to brand drugs, more Medicare Part D participants selected generic drugs to fill prescriptions covered by the drug benefit program last year than in 2005, according to new data from the Centers for Medicare & Medicaid Services (CMS).
Motivated by lower co-payments for inexpensive alternatives to brand drugs, more Medicare Part D participants selected generic drugs to fill prescriptions covered by the drug benefit program last year than in 2005, according to new data from the Centers for Medicare & Medicaid Services (CMS).
The Centers for Medicare & Medicaid Services (CMS) must strengthen its guidance regarding an exception to Medicaid price-reporting requirements to prevent drug companies’ abuse of that provision, key lawmakers say.
Alex Azar, HHS’ deputy secretary, is resigning, leaving a void in the agency’s efforts to continue implementation of the Part D prescription drug plan, sources say.
Using a simple heart rhythm test to determine which patients should receive implantable cardioverter-defibrillators (ICDs) could save the federal government nearly $1 billion per year in Medicare reimbursement costs, according to a new study.